Product image of Mozobil (Plerixafor) supplied by GNH India

Mozobil

Active Ingredient:
Plerixafor
Origin:
EU

Mozobil (Plerixafor)

Plerixafor, the active ingredient in Mozobil, is a CXCR4 antagonist presented as a 0.24 mg/mL injection solution for subcutaneous use. It mobilizes hematopoietic stem cells for autologous transplantation in patients with non‑Hodgkin lymphoma and multiple myeloma. The drug is indicated for mobilizing hematopoietic stem cells in preparation for autologous stem cell transplantation.

GNH India supplies Mozobil as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sanofi B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mozobil (plerixafor) is used to mobilize hematopoietic stem cells in hematologic malignancies.

  • Non‑Hodgkin lymphoma: mobilizes stem cells for autologous transplantation.
  • Multiple myeloma: mobilizes stem cells for autologous transplantation.
  • Other eligible hematologic cancers: facilitates collection of peripheral blood stem cells for autologous transplant.

How It Works

  • Plerixafor antagonizes the CXCR4 receptor on hematopoietic stem cells, blocking its interaction with stromal cell‑derived factor‑1 (SDF‑1) in the bone‑marrow niche. This disruption releases stem cells into the peripheral circulation, enhancing their collection for autologous transplantation. The effect appears within hours after subcutaneous administration and is additive to granulocyte‑colony stimulating factor when used together.

Side Effects

Plerixafor may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Injection site pain: mild discomfort at the subcutaneous injection site.
  • Nausea: transient feeling of sickness.
  • Diarrhea: loose stools.
  • Fatigue: general tiredness.
  • Headache: mild to moderate head pain.

Serious or Rare Side Effects

  • Hypersensitivity reactions: rash, urticaria, or anaphylaxis.
  • Splenic rupture: rare but potentially life‑threatening.
  • Severe leukocytosis: markedly elevated white blood cell count.
  • Thromboembolic events: blood clots in veins or arteries.

Precautions & Warnings

When using Mozobil, several precautions should be observed to ensure patient safety and product integrity.

  • Patient assessment: evaluate hematologic status and eligibility for stem cell mobilization.
  • Concomitant G‑CSF: coordinate timing with granulocyte‑colony stimulating factor as recommended.
  • Monitoring: observe for signs of hypersensitivity and injection‑site reactions during and after administration.
  • Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited.
  • Renal function: adjust use in patients with impaired renal clearance, following clinical guidance.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Plerixafor can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Concurrent use with strong CYP3A4 inhibitors: may increase systemic exposure; caution advised.
  • Live vaccines: immunosuppression from stem cell mobilization may reduce vaccine efficacy; avoid concurrent administration.

Moderate Interactions (Monitor Closely)

  • G‑CSF agents: additive effect on stem cell mobilization; dosing schedule should be coordinated.
  • Anticoagulants: monitor for bleeding risk if splenic rupture occurs.
  • Diuretics: assess fluid balance as plerixafor may cause transient shifts.

Frequently Asked Questions

Mozobil (plerixafor) is used to mobilize hematopoietic stem cells from the bone marrow into the peripheral blood, enabling collection of these cells for autologous stem cell transplantation in patients with certain hematologic cancers such as non‑Hodgkin lymphoma and multiple myeloma.

Plerixafor blocks the CXCR4 receptor on stem cells, preventing its binding to stromal cell‑derived factor‑1 (SDF‑1). This disruption releases stem cells into the bloodstream, increasing their availability for collection and subsequent transplantation.

The dose of Mozobil is determined by the prescribing clinician based on the patient’s weight, clinical condition, and the planned stem cell collection protocol. Specific dosing regimens are not disclosed here.

Safety data for plerixafor in pregnancy and lactation are limited. Use is generally avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant, and only under close medical supervision.

Enquiries are submitted via the product page on gnhindia.com, where you specify the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Mozobil is a CXCR4 antagonist, whereas other mobilizers such as G‑CSF act through different pathways (e.g., stimulating granulocyte colony‑forming cells). Plerixafor often provides a rapid and synergistic increase in stem‑cell yield when used in combination with G‑CSF, especially in patients who are poor mobilizers with G‑CSF alone.

Mozobil should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and do not freeze or shake the solution. Follow any additional handling instructions provided with the product.

Mozobil is supplied as a sterile injection solution for subcutaneous use. It is typically injected into the abdomen or thigh, following the dosing schedule and administration technique prescribed by the treating physician.

Serious risks include hypersensitivity reactions such as anaphylaxis, splenic rupture, severe leukocytosis, and thromboembolic events. Patients should be monitored closely for signs of these conditions during and after administration.

Mozobil should not be used in patients with known hypersensitivity to plerixafor or any of its excipients, in individuals with uncontrolled infections, or in those where the risks of stem‑cell mobilization outweigh the potential benefits, as determined by the treating physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Plerixafor

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT